Tevogen Bio Holdings (DE:G280)
FRANKFURT:G280
G280 Stock Chart & Stats
€0.31
€0.24(19.35%)
At close: 4:00 PM EST
€0.31
€0.24(19.35%)
Day’s Range― - ―
52-Week Range€6.90 - €61.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€32.67M
Enterprise Value€35.50M
Total Cash (Recent Filing)€692.30K
Total Debt (Recent Filing)€3.07M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.84
Shares Outstanding4,187,505
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High-value T-cell Immunotherapy FocusTevogen’s focus on precision T‑lymphocyte (CTL) therapies targets enduring unmet needs in oncology and infectious disease. A successful T‑cell platform can deliver durable clinical benefits and scalable product opportunities, creating a long-term commercial pathway distinct from commodity therapeutics.
Maintained Nasdaq Listing Via Reverse SplitRestoring Nasdaq Global Market compliance preserves access to a regulated capital market and investor visibility—critical for biotechs that require frequent external funding. This structural action reduces near-term delisting risk and keeps the company positioned to raise capital when needed.
Reduced Debt Versus 2022–2023Lower debt levels improve financial flexibility and reduce fixed charge burden, which matters for an early‑stage biotech reliant on external financing. Even with negative equity, reduced leverage eases short‑term liquidity pressure and modestly lengthens runway for developmental progress.
Bears Say
No Revenue; Persistent Operating LossesAbsence of product revenue and recurring operating losses indicate the business remains pre-commercial and fully R&D‑driven. This structurally extends reliance on funding rounds, increases dilution risk, and means operational progress must be demonstrated via clinical milestones rather than cash flow.
Negative Stockholders' EquitySustained negative equity signals accumulated deficits and constrains balance sheet flexibility. It distorts leverage metrics, may limit borrowing capacity, and elevates the probability of equity‑raising or restructuring—material for long‑term financial stability and investor confidence.
Sustained Cash Burn (~$12M TTM)Ongoing negative operating and free cash flow at about $12M TTM creates persistent funding needs. For a small, pre-revenue biotech with limited assets, this drives regular capital raises, dilutive financing risk, and execution dependence on successful clinical progress to justify further investment.
Tevogen Bio Holdings News
G280 FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was €6.90 and its highest was €61.50 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is €32.67M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Aug 13, 2026 which is in 68 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Jun 03, 2026. The company reported -€1.388 earnings per share for the quarter, beating the consensus estimate of -€2.273 by €0.885.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 4,187,505 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -€1.388 in its last earnings report, beating expectations of -€2.273. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in DE:G280
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.20%
12-Months-Change
Fundamentals
Return on Equity
241.39%
Trailing 12-Months
Asset Growth
20.81%
Trailing 12-Months
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―
Options Prices
Currently, No data available
---